[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100404407":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":71,"collaborators":29,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":29,"enrollmentInfo":84,"targetDuration":29,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":47,"whyStopped":29,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase I MRI Simulation","EXPERIMENTAL","This research study involves a screening period to determine eligibility.\n\n\\- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.",[13,14],"Device: MRI Simulator","Radiation: Radiation Therapy",{"label":16,"type":10,"description":17,"interventionNames":18},"Phase II MR Simulation Protocol: Track A","MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Phase II MR Simulation Protocol: Track B","Adjusted Margin or \u002F Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)",[13,14],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DEVICE","MRI Simulator","Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.",[9,16,20],null,{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":29},"RADIATION","Radiation Therapy","In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and\u002For RT will vary per disease site and will be pre-specified in the subprotocols.",[9,16,20],[36],{"name":37,"affiliation":5,"role":38},"Raymond Mak, MD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":29,"email":43},"CONTACT","617-632-5734","rmak@partners.org",[45,62],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Brigham and Women Hospital","RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-71.05977,42.35843,{"lat":57,"lon":56},[60,61],{"name":37,"role":41,"phone":29,"phoneExt":29,"email":43},{"name":37,"role":38,"phone":29,"phoneExt":29,"email":29},{"facility":63,"status":47,"city":48,"state":49,"zip":64,"country":51,"countryCode":52,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Dana Farber Cancer Institute","02215",{"type":54,"coordinates":66},[56,57],{"lat":57,"lon":56},[69,70],{"name":37,"role":41,"phone":29,"phoneExt":29,"email":43},{"name":37,"role":38,"phone":29,"phoneExt":29,"email":29},{"type":38,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Raymond Mak","Principal Investigator","100404407","jump-mr-simulation-for-radiation-therapy-master-protocol-100404407",false,"NCT04545957","Jump: MR Simulation For Radiation Therapy Master Protocol","Judging MR Simulation Procedures: A Phase I-II Study of the Use of Magnetic Resonance Imaging Simulation in the Planning of Radiation Treatments","JUMP","Inclusion Criteria:\n\n* Participants must have a confirmed malignancy requiring radiation therapy.\n* Age: 18 years or older\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Disease-specific eligibility criteria will be specified in the appropriate subprotocol.\n\nExclusion Criteria:\n\n* For MRI involving contrast, history of allergic reactions attributed to gadolinium based IV contrast. Note: If patient will not receive contrast, this is not applicable\n* Participants who cannot undergo an MRI\n* Disease-specific exclusion criteria will be specified in the appropriate subprotocol","ALL","18 Years",{"count":85,"type":86},86,"ESTIMATED","INTERVENTIONAL",[89],"NA","This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.",[92,93,94,95],"Prostate Cancer","Recurrent Adenocarcinoma","Liver Cancer","Head and Neck Cancer",[92,93,94,95],"2026-07-17",{"date":99,"type":100},"2026-07-20","ACTUAL",{"date":102,"type":100},"2020-10-14",{"date":104,"type":86},"2030-10-22",{"name":5,"class":6},2]